{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Limited"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Extensive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Number of participant who experienced chronic graft versus host disease (GVHD) following stem cell transplant The diagnosis of clinical features of chronic-GVHD was determined prospectively and classified retrospectively into limited or extensive based on the Revised Seattle Classification. Chronic GvHD severity categorized as \"limited\" is defined as: localized skin lesions with or without limited hepatic involvement and \"extensive\" is defined as: generalized skin involvement, major hepatic complications, or involvement of any other organ.","groups":[{"description":"Subjects received a nonmyeloablative preparative regimen of alemtuzumab 30mg IV three times a week for two weeks followed by fludarabine 25mg/m\\^2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x10\\^6 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis will be used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).","id":"OG000","title":"Stem Cell Transplant Therapy With Campath-1H"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analyses included only those participants that engrafted and survived over 100 days","reportingStatus":"POSTED","timeFrame":"Day 100 up to 3 years","title":"Number of Participant Who Experienced Chronic Graft Versus Host Disease","type":"SECONDARY","unitOfMeasure":"Participants"}